Back to Back Issues Page
Stem Cell Trial Milestone: One Million
September 18, 2013

Stem Cell Trial Milestone: One Million

A new milestone in the Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration occurred just days ago on September 11, 2013.

Adult (Non-Embryonic) Stem Cells

The Phase I/II clinical trial is called a dose-escalating study. Eligible patients are injected with a single dose of HuCNS-SC cells into one affected eye. So far 4 patients with advanced dry macular degeneration have received a one time dose of 200,000 cells.

A Phase I study's purpose is to purely evaluate the safety of a therapy or drug. Preliminary results are showing that the cells are well tolerated and the reports are stating that there have been no signs of adverse effects or complications. One of the main concerns of stem cell therapy is the formation of tumors. Patients will be followed for at least 4 years to observe any long term effects.

The study is cautiously moving forward by injecting the 5th patient with 1 million stem cells - 5 times the amount received by the first 4 patients.

Stephen Huhn, the Vice President of CNS Clinical Research at StemCells Inc, stated," Advancing to the high dose, which is a five-fold increase from the low dose, is an important milestone in this trial. Testing a cell dose of this magnitude in all the remaining patients planned for the trial will enhance our ability to assess the effect of the cells on visual acuity."

Find out who is eligible to be a candidate for the study and the study location sites here:

Macular Degeneration and Stem Cells

P.S. Please hit the Facebook "Like" Button if you like the page! Thanks so much for subscribing to Macular Degeneration News.

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page